1 / 8

Tracking Biosimilar Market Opportunities Using Drug Pipeline Intelligence

The biosimilar market is getting bigger, faster, and honestly a little chaotic. Patent cliffs are coming one after another, biologics are losing exclusivity across the world, and every pharma company wants a piece of the action. But even though the opportunity is huge, figuring out where the next biosimilar win really is can feel like trying to read a map in the dark. Thatu2019s where drug pipeline intelligence completely changes the game. More Info: https://clival.com/blog/tracking-biosimilar-market-opportunities-using-drug-pipeline-intelligence

ClivalDatabase
Télécharger la présentation

Tracking Biosimilar Market Opportunities Using Drug Pipeline Intelligence

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Tracking Biosimilar Market Opportunities Using Drug Pipeline Intelligence

  2. INTRODUCTION The biosimilar market is getting bigger, faster, and honestly a little chaotic. Patent cliffs are coming one after another, biologics are losing exclusivity across the world, and every pharma company wants a piece of the action. But even though the opportunity is huge, figuring out where the next biosimilar win really is can feel like trying to read a map in the dark.

  3. Why Tracking Biosimilar Opportunities Is So Hard? On paper, biosimilars sound easy: wait for a biologic to lose its exclusivity, design a copy, get approval, and sell. But in real life, it’s nowhere near that simple. Here’s why it gets messy: • Patent timelines keep changing because of lawsuits, settlements, and extensions. • Clinical pipelines move fast, with new competitors entering out of nowhere. • Regulatory data is scattered across multiple agencies and countries. • Market conditions differ for Europe, the U.S., India, LATAM, and Southeast Asia.

  4. How Drug Pipeline Intelligence Helps Spot Biosimilar Market Opportunities? 1. Tracking LOE and Patent Expiries (The Real Starting Point) 2. Understanding the Competitive Landscape Before You Jump In 3. Monitoring Global Regulatory Filings and Approvals 4. Evaluating Scientific and Technological Requirements 5. Mapping API and CDMO Availability (A Step Most People Forget)

  5. How Companies Use Market Intelligence to Make Better Biosimilar Decisions? • Identify biologics losing exclusivity soon • Score each molecule based on market size, unmet need, and competitive intensity • Check pipeline saturation using developer-level analytics • Scan regulatory landscapes to find the easiest markets • Evaluate scientific and technical requirements • Identify capable CDMOs and suppliers • Build a go/no-go strategy • Track updates continuously with alerts

  6. Conclusion The biosimilar landscape is expanding fast, but so is the competition. Companies that rely on slow updates or outdated data will always be a step behind. But those who use drug pipeline intelligence can spot opportunities early, avoid market saturation, reduce development risk, and plan smarter launches.

  7. Website : WWW.clival.com • www.lifescienceintellipedia.com • www.chemxpert.com • Location:- C-89, Sector-65 Noida-U.P. 201301 (India) • E-Mail:- info@lifescienceintellipedia.com | sales@lifescienceintellipedia.com • Phone:- +91-120-6631301-335 • Mob No:- +91-9990237670

  8. THANK YOU!

More Related